Literature DB >> 32769142

Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases.

F Heath Damron1, Mariette Barbier1, Purnima Dubey2, Kathryn M Edwards3, Xin-Xing Gu4, Nicola P Klein5, Kristina Lu4, Kingston H G Mills6, Marcela F Pasetti7, Robert C Read8, Pejman Rohani9,10, Peter Sebo11, Eric T Harvill12.   

Abstract

Despite high vaccine coverage in many parts of the world, pertussis is resurging in a number of areas in which acellular vaccines are the primary vaccine administered to infants and young children. This is attributed in part to the suboptimal and short-lived immunity elicited by acellular pertussis vaccines and to their inability to prevent nasal colonization and transmission of the etiologic agent Bordetella pertussis In response to this escalating public health concern, the National Institute of Allergy and Infectious Diseases held the workshop "Overcoming Waning Immunity in Pertussis Vaccines" in September 2019 to identify issues and possible solutions for the defects in immunity stimulated by acellular pertussis vaccines. Discussions covered aspects of the current problem, gaps in knowledge and possible paths forward. This review summarizes presentations and discussions of some of the key points that were raised by the workshop.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32769142      PMCID: PMC7454230          DOI: 10.4049/jimmunol.2000676

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.

Authors:  A K H Berstad; J Holst; L O Frøholm; I L Haugen; E Wedege; F Oftung; B Haneberg
Journal:  J Med Microbiol       Date:  2000-02       Impact factor: 2.472

2.  Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population.

Authors:  Rei Fumimoto; Nao Otsuka; Tomimasa Sunagawa; Keiko Tanaka-Taya; Hajime Kamiya; Kazunari Kamachi
Journal:  Vaccine       Date:  2019-03-28       Impact factor: 3.641

3.  Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.

Authors:  Xin-Xing Gu; Stanley A Plotkin; Kathryn M Edwards; Alessandro Sette; Kingston H G Mills; Ofer Levy; Andrea J Sant; Annie Mo; William Alexander; Kristina T Lu; Christopher E Taylor
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

4.  Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells.

Authors:  Aideen C Allen; Mieszko M Wilk; Alicja Misiak; Lisa Borkner; Dearbhla Murphy; Kingston H G Mills
Journal:  Mucosal Immunol       Date:  2018-08-20       Impact factor: 7.313

5.  Acellular Pertussis Vaccine Effectiveness Over Time.

Authors:  Ousseny Zerbo; Joan Bartlett; Kristin Goddard; Bruce Fireman; Edwin Lewis; Nicola P Klein
Journal:  Pediatrics       Date:  2019-06-10       Impact factor: 7.124

6.  The impact of past vaccination coverage and immunity on pertussis resurgence.

Authors:  Matthieu Domenech de Cellès; Felicia M G Magpantay; Aaron A King; Pejman Rohani
Journal:  Sci Transl Med       Date:  2018-03-28       Impact factor: 17.956

7.  Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.

Authors:  Ang Lin; Danijela Apostolovic; Maja Jahnmatz; Frank Liang; Sebastian Ols; Teghesti Tecleab; Chenyan Wu; Marianne van Hage; Ken Solovay; Keith Rubin; Camille Locht; Rigmor Thorstensson; Marcel Thalen; Karin Loré
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

8.  Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction.

Authors:  Gayatri Amirthalingam; Helen Campbell; Sonia Ribeiro; Norman K Fry; Mary Ramsay; Elizabeth Miller; Nick Andrews
Journal:  Clin Infect Dis       Date:  2016-12-01       Impact factor: 9.079

9.  Analysis of the In Vivo Transcriptome of Bordetella pertussis during Infection of Mice.

Authors:  Ting Y Wong; Jesse M Hall; Evan S Nowak; Dylan T Boehm; Laura A Gonyar; Erik L Hewlett; Joshua C Eby; Mariette Barbier; F Heath Damron
Journal:  mSphere       Date:  2019-04-17       Impact factor: 4.389

10.  Controlled Human Infection With Bordetella pertussis Induces Asymptomatic, Immunizing Colonization.

Authors:  Hans de Graaf; Muktar Ibrahim; Alison R Hill; Diane Gbesemete; Andrew T Vaughan; Andrew Gorringe; Andrew Preston; Annemarie M Buisman; Saul N Faust; Kent E Kester; Guy A M Berbers; Dimitri A Diavatopoulos; Robert C Read
Journal:  Clin Infect Dis       Date:  2020-07-11       Impact factor: 9.079

View more
  5 in total

1.  Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness.

Authors:  Ousseny Zerbo; Bruce Fireman; Nicola P Klein
Journal:  Expert Rev Vaccines       Date:  2021-10-08       Impact factor: 5.683

2.  Long-Term Analysis of Pertussis Vaccine Immunity to Identify Potential Markers of Vaccine-Induced Memory Associated With Whole Cell But Not Acellular Pertussis Immunization in Mice.

Authors:  Kelly L Weaver; Catherine B Blackwood; Alexander M Horspool; Gage M Pyles; Emel Sen-Kilic; Emily M Grayson; Annalisa B Huckaby; William T Witt; Megan A DeJong; M Allison Wolf; F Heath Damron; Mariette Barbier
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

3.  Bbvac: A Live Vaccine Candidate That Provides Long-Lasting Anamnestic and Th17-Mediated Immunity against the Three Classical Bordetella spp.

Authors:  Monica C Gestal; Laura K Howard; Kalyan K Dewan; Eric T Harvill
Journal:  mSphere       Date:  2022-02-23       Impact factor: 4.389

Review 4.  Precision Vaccine Development: Cues From Natural Immunity.

Authors:  Soumik Barman; Dheeraj Soni; Byron Brook; Etsuro Nanishi; David J Dowling
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

5.  Pertussis Vaccine Candidate Based on Outer Membrane Vesicles Derived From Biofilm Culture.

Authors:  Francisco Carriquiriborde; Pablo Martin Aispuro; Nicolás Ambrosis; Eugenia Zurita; Daniela Bottero; María Emilia Gaillard; Celina Castuma; Erika Rudi; Aníbal Lodeiro; Daniela F Hozbor
Journal:  Front Immunol       Date:  2021-09-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.